Beasley, Allen, Crow, Methvin, Portis & Miles, P.C.

A Food and Drug Administration (FDA) advisory committee has narrowly voted to recommend that the indication for Eli Lilly’s antidepressant Cymbalta (duloxetine) be expanded to include use as a treatment for chronic musculoskeletal pain. The Anesthetic and Life Support Drugs Advisory Committee also voted that the benefits were minimal but outweighed the risks, which includes a black box warning of suicidality in children, adolescents and young adults; a potential for liver damage; and a risk of developing the rare skin disease Stevens Johnson Syndrome (SJS) and its more serious form, toxic epidermal necrolysis (TEN).

Read the rest of this entry »

A New Hampshire jury will decide whether a drug company is liable for $24 million in damages from its prescription anti-inflammatory medication that caused a woman to suffer from a severe reaction that caused painful burns to break out on her skin and internal organs and made her go blind.

Read the rest of this entry »

“For me, just being here alive is a story to tell,” Karyl Bell told WNYT-TV. In October 2009, the then-17-year-old unexpectedly developed a rash on her face. Her tongue swelled and she had trouble swallowing and breathing. Her condition quickly worsened. Red, painful blisters broke out on her body. Lesions in her eyes caused her eyes to swell shut. All doctors could tell her worried mother was to sit by as the reaction ran its course and, “hope for the best.”

Read the rest of this entry »